Literature DB >> 25360726

Is pulmonary hypertension a metabolic disease?

Jarrod Barnes1, Raed A Dweik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25360726      PMCID： PMC4299590          DOI： 10.1164/rccm.201409-1702ED

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  20 in total

1.  Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells.

Authors:  Hoe-Sup Byun; Susan Pyne; Neil Macritchie; Nigel J Pyne; Robert Bittman
Journal:  Medchemcomm       Date:  2013       Impact factor: 3.597

2.  Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension.

Authors:  Gustavo A Heresi; Metin Aytekin; Jennie Newman; Joseph DiDonato; Raed A Dweik
Journal:  Am J Respir Crit Care Med       Date:  2010-05-06       Impact factor: 21.405

3.  An official American Thoracic Society Statement: pulmonary hypertension phenotypes.

Authors:  Raed A Dweik; Sharon Rounds; Serpil C Erzurum; Stephen Archer; Karen Fagan; Paul M Hassoun; Nicholas S Hill; Marc Humbert; Steven M Kawut; Michael Krowka; Evangelos Michelakis; Nicholas W Morrell; Kurt Stenmark; Rubin M Tuder; John Newman
Journal:  Am J Respir Crit Care Med       Date:  2014-02-01       Impact factor: 21.405

Review 4.  Novel and emerging therapies for pulmonary hypertension.

Authors:  Soni Savai Pullamsetti; Ralph Schermuly; Ardeschir Ghofrani; Norbert Weissmann; Friedrich Grimminger; Werner Seeger
Journal:  Am J Respir Crit Care Med       Date:  2014-02-15       Impact factor: 21.405

5.  Dysregulated lipid metabolism in cancer.

Authors:  Feng Zhang; Guangwei Du
Journal:  World J Biol Chem       Date:  2012-08-26

6.  Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension.

Authors:  Gopinath Sutendra; Sebastien Bonnet; Gael Rochefort; Alois Haromy; Karalyn D Folmes; Gary D Lopaschuk; Jason R B Dyck; Evangelos D Michelakis
Journal:  Sci Transl Med       Date:  2010-08-11       Impact factor: 17.956

7.  Causes and circumstances of death in pulmonary arterial hypertension.

Authors:  Adriano R Tonelli; Vineesha Arelli; Omar A Minai; Jennie Newman; Nancy Bair; Gustavo A Heresi; Raed A Dweik
Journal:  Am J Respir Crit Care Med       Date:  2013-08-01       Impact factor: 21.405

8.  High levels of hyaluronan in idiopathic pulmonary arterial hypertension.

Authors:  Metin Aytekin; Suzy A A Comhair; Carol de la Motte; Sudip K Bandyopadhyay; Carol F Farver; Vincent C Hascall; Serpil C Erzurum; Raed A Dweik
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-09-05       Impact factor: 5.464

9.  Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment.

Authors:  Anne Kultti; Chunmei Zhao; Netai C Singha; Susan Zimmerman; Ryan J Osgood; Rebecca Symons; Ping Jiang; Xiaoming Li; Curtis B Thompson; Jeffrey R Infante; Michael A Jacobetz; David A Tuveson; Gregory I Frost; H Michael Shepard; Zhongdong Huang
Journal:  Biomed Res Int       Date:  2014-07-24       Impact factor: 3.411

10.  Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Stephen L Archer; Albert Defelice; Steven Evans; Monica Fiszman; Thomas Martin; Muriel Saulnier; Marlene Rabinovitch; Ralph Schermuly; Duncan Stewart; Hubert Truebel; Gennyne Walker; Kurt R Stenmark
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017
View more
  4 in total

Review 1.  Novel methods in pulmonary hypertension phenotyping in the age of precision medicine (2015 Grover Conference series).

Authors:  Jarrod W Barnes; Adriano R Tonelli; Gustavo A Heresi; Jennie E Newman; Noël E Mellor; David E Grove; Raed A Dweik
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

2.  Bone Morphogenic Protein Type 2 Receptor Mutation-Independent Mechanisms of Disrupted Bone Morphogenetic Protein Signaling in Idiopathic Pulmonary Arterial Hypertension.

Authors:  Jarrod W Barnes; Elif T Kucera; Liping Tian; Noël E Mellor; Nina Dvorina; William W Baldwin; Micheala A Aldred; Carol F Farver; Suzy A A Comhair; Metin Aytekin; Raed A Dweik
Journal:  Am J Respir Cell Mol Biol       Date:  2016-10       Impact factor: 6.914

3.  Sildenafil reduces signs of oxidative stress in pulmonary arterial hypertension: Evaluation by fatty acid composition, level of hydroxynonenal and heart rate variability.

Authors:  Khrystyna Semen; Olha Yelisyeyeva; Iwona Jarocka-Karpowicz; Danylo Kaminskyy; Lyubomyr Solovey; Elzbieta Skrzydlewska; Ostap Yavorskyi
Journal:  Redox Biol       Date:  2015-11-22       Impact factor: 11.799

4.  Plasma metabolomic profile in chronic thromboembolic pulmonary hypertension.

Authors:  Gustavo A Heresi; Jacob T Mey; John R Bartholomew; Ihab S Haddadin; Adriano R Tonelli; Raed A Dweik; John P Kirwan; Satish C Kalhan
Journal:  Pulm Circ       Date:  2020-02-04       Impact factor: 3.017
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.